tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
SCYNEXIS Reports Improved Financials Amidst Strategic Developments
PremiumCompany AnnouncementsSCYNEXIS Reports Improved Financials Amidst Strategic Developments
2M ago
Scynexis reports Q2 EPS (14c), consensus (19c)
Premium
The Fly
Scynexis reports Q2 EPS (14c), consensus (19c)
2M ago
SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment
Premium
Company Announcements
SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment
2M ago
Scynexis resumes patient dosing in Phase 3 MARIO study
PremiumThe FlyScynexis resumes patient dosing in Phase 3 MARIO study
4M ago
SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations
Premium
Ratings
SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations
5M ago
SCYNEXIS Faces Challenges Amidst Antifungal Developments
Premium
Company Announcements
SCYNEXIS Faces Challenges Amidst Antifungal Developments
5M ago
SCYNEXIS Reports 2024 Financial Results and Updates
PremiumCompany AnnouncementsSCYNEXIS Reports 2024 Financial Results and Updates
7M ago
Scynexis initiates dosing in Phase 1 trial of SCY-247
Premium
The Fly
Scynexis initiates dosing in Phase 1 trial of SCY-247
10M ago
Scynexis reports Q3 EPS (6c), consensus (7c)
Premium
The Fly
Scynexis reports Q3 EPS (6c), consensus (7c)
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100